Endocrine Abstracts

Historically, many radionuclide therapy (RNT) procedures practiced in nuclear medicine have employed standardised amounts of a radionuclide for the therapy. This often neglects factors such as patient size, tumour burden, rate of disease progression and intra-lesional heterogeneity. At the opposite end of the spectrum, treatment procedures using external beam radiotherapy (EBRT) have become increasingly individualised to maximise the dose to target whilst minimising radiation ...

The World Cancer Research Fund International predicts the number of prostate cancer (PCa) cases will approach 1.7 million by 2030. Patient-specific staging drives the demand for sensitive and specific imaging of PCa including intraprostatic disease as well as local and distant metastases. Definitive therapy such as surgery or radiation is highly effective, but if the tumor escapes the gland, treatment options are limited. New imaging approaches that can more accurately assess ...

Since its introduction as an imaging agent in humans in 2011, Ga PSMA PET CT has been rapidly embraced clinically for the imaging of prostate cancer both in the setting of biochemical failure and as a staging procedure. The increased sensitivity of the technique in comparison to previously available imaging modalities, and the startling images, have led to a paradigm shift in the treatment of prostate cancer, particularly in the setting of biochemical failure. This talk will g...

Introduction: Conventional imaging for prostate cancer typically utilizes cross-sectional CT and MRI scanning, along with Tc99 bone scanning for bone metastases. All of these modalities have relatively poor sensitivity and specificity, particularly for men with suspected recurrence following radical prostatectomy or radiotherapy. PSMA PET is rapidly emerging as a superior imaging option.Objective: To give a clinical perspective of the role PSMA PET for s...

Currently national and international guidelines for imaging procedures for high risk and advanced prostate cancer (PCa) include abdomino-pelvic cross sectional imaging, multiparametric prostate MRI, bone scintigraphy and in the case of therapy monitoring of mCRPC whole body cross-sectional imaging mainly by means of computed tomography. Positron emission tomography (PET) has become increasingly important in the work-up of prostate cancer. Recently, a 68Gallium-label...

Abstract unavailable at time of publishing....

Stanford University has installed the first GE SIGNA PET+MRI world-wide in December 2013 as part of a comprehensive research program expanding the successful Radiological Sciences Laboratory (RSL) MRI research and the Molecular Imaging Program at Stanford (MIPS) expertise. The presentation will address the challenges, opportunities and success stories of the program after 3 years of research activities....

Background: Despite its desirable half-life and high-energy Auger electrons, 67Ga has been neglected as a therapeutic Auger electron emitter, due in part to lack of suitable chelators and targeting molecules.Objective: Here, 67Ga is compared with Auger electron emitter 111In as a therapeutic radionuclide in prostate cancer and breast cancer cell lines.Method: Plasmid pBR322 studies allowed direct co...

Purpose: The purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer (mCRPC).Methods: 31 mCRPC patients with progressive disease despite second line hormonal therapy and/or Docetaxel chemotherapy were recruited for the study. All patients underwent diagnostic68Ga-PSMA-HBED-CCPET/CT, prior to inclusion for therapy. Inclu...

Aim: Given the aggressive biological features of metastatic prostate cancer, a more aggressive treatment with [177Lu]-PSMA might be appropriate.Materials and methods: We have treated 15 patients (mean age 69 years) with intended 3 cycles of [177Lu]-PSMA every 4 weeks. All patients have been examined with [68Ga]-PSMA PET/MRI to validate PSMA expression of all metastatic lesions. We monitored haemoglobin (Hb), platelets (Pl), leucocytes and creatinine for ...

Aim: To evaluate the use of PET/CT with 64CuCl2 in recurring prostate cancer after surgery in patients with low PSA level (<2).Introduction: Previous works* demonstrated as 64CuCl2 is a PET probe in prostate cancer in mice with xenografts of prostate cancer.Moreover, it was described** in seven patients the role of 64CuCl2 PET/CT in staging of prostate cancer.Met...

PSMA-11 belongs to the substance class of peptidomimetic prostate-specific membrane antigen (PSMA) inhibitors. In general, the class of urea-based PSMA inhibitors was firstly described by Kozikowski et al. in 2001 [1] and one of the first preclinical imaging studies using PSMA radioligands in PSMA-positive tumor xenografts were reported by Pomper et al. in 2005 [2]. PSMA is an optimal target both for imaging and therapy of prostate cancer. The now well establ...

Ga-68 PSMA PET/CT is producing images with astounding tumour-to-background contrast for staging prostate cancer. Defining the extent of prostate cancer spread with imaging is of utmost importance for therapeutic decision-making. Relapse following curative-intent treatment is not uncommon despite careful selection of patients with CT, MRI and bone scintigraphy prior to surgery or radiotherapy, highlighting the limited sensitivity of conventional imaging. Imaging with PSMA-PET m...

Ga-68 labelled urea-based inhibitors of the prostate specific membrane antigen (PSMA), such as 68Ga-HBED-PSMA-11, are promising peptides for targeting prostate cancer. The tris(hydroxypyridinone) (THP) ligand rapidly complexes 68Ga3+ at room temperature, at very low concentration and over a wide pH range, making it possible for the direct elution from a 68Ge/68Ga generator into a cold radiopharmaceutical kit in one step wi...

Aim: To analyze the safety, efficacy and dosimetry of Lu-177 labeled prostate specific membrane antigen (PSMA) ligand 617 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC), in comparison with Lu-177 PSMA I&T.Methods: Lu-177 PSMA-617 radioligand therapy (PRLT) was performed in 64 mCRPC patients. The median administered activity per treatment was 6 GBq. Ga-68 PSMA PET/CT was used for patient selection and follow-up. H...

Objectives: Copper-64 (64Cu, T1/2=12.7 h; Eβ+ max =0.65 MeV (17.9%); Eβ− max =0.57 MeV (39%)) is suitable for in-vivo PET imaging. Prostate specific membrane antigen (PSMA) is significantly over-expressed in undifferentiated prostate cancer tissue. We report the initial molecular imaging results with 64Cu-PSMA PET/CT in patients with prostate cancer.Methods: 64Cu labeled PSMA (mean administered ra...

Objectives: DOTAMZOL is a DOTA-conjugated bisphosphonate which can be used for diagnostic (44Sc, 68Ga) or therapeutic (177Lu) applications. The aim of this study was to evaluate the adaption of the radiolabelling process on an automated module utilizing NaCl-post processing, with regard to clinical application and additional radiation protection point of view.Methods: 68Ga was obtained from a 1.5 yea...